Advances in paraneoplastic neurological syndromes

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 614-620

  Honnorat, Jérôme ^a,b   Cartalat Carel, Stéphanie ^a  

^a Hopital Neurologique   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Antineuronal antibodies; Paraneoplastic neurological disease; Small cell lung carcinoma

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN; STEROID;

CEREBELLAR ATAXIA; CHRONIC GASTROINTESTINAL PSEUDOOBSTRUCTION; EATON LAMBERT SYNDROME; ENCEPHALOMYELITIS; HUMAN; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; MYOCLONUS; OPSOCLONUS; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; RETINOPATHY; REVIEW; SENSORY NEUROPATHY; STIFF MAN SYNDROME;

HUMANS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 8344281973     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000142486.89472.eb     Document Type: Review

References (74)

1. Posner JB: Neurologic complications of cancer. Philadelphia, PA: FA Davis Co; 1995.
2. Darnell RB, Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554.
3. Vianello M, Vitaliani R, Pezzani R, et al.: The spectrum of antineuronal autoantibodies in a series of neurological patients. J Neurol Sci 2004, 220:29-36. The authors studied among 882 patients the range of neurological disorders expressing antineuronal antibodies to identify subgroups of patients.
4. Graus F, Delattre JY, Antoine JC, et al.: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140. An international panel of neurologists reviewed the diagnostic criteria of PNS, recommended new criteria for consensus classification, reviewed all reported paraneoplastic antibodies, established the conditions to identify those that would be labeled well characterized. The proposed criteria should help clinicians in the classification of their patients and the prospective and retrospective analysis of PNS cases.
5. Stich O, Graus F, Rasiah C, et al.: Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol 2003, 141:165-169.
6. Posner JB, Furneaux HM: Paraneoplastic syndromes. Res Publ Assoc Res Nerv Ment Dis 1990, 68:187-219.
7. O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988, 111:577-596.
8. Newsom-Davis J: Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 2004, 160:177-180. An extensive review of new advances in LEMS.
9. Fukuda T, Motomura M, Nakao Y, et al.: Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53:21-28.
10. Graus F, Lang B, Pozo-Rosich P, et al.: P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59:764-766.
11. Peterson K, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
12. Rojas I, Graus F, Keime-Guibert F, et al.: Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55:713-715.
13. Bernai F, Shams'ili S, Rojas I, et al.: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003, 60:230-234. This multicenter study broadens the clinical and immunologic associations of patients with Tr-Ab.
14. Wiener V, Honnorat J, Pandolfo M, et al.: Myorhythmia associated with Hodgkin's lymphoma. J Neurol 2003, 250:1382-1384. This article describes clinical specificities of one patient with Tr-Ab.
15. Mason WP, Graus F, Lang B, et al.: Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton mysthenic syndrome. Brain 1997, 120:1279-1300.
16. Honnorat J, Antoine JC, Derrington E, et al.: Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr 1996, 61:270-278.
17. Yu Z, Kryzer TJ, Griesmann GE, et al.: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154.
18. Bataller L, Wade DF, Graus F, et al.: Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782. This study presents data showing the clear association among anti-Zic4 antibodies, cerebellar ataxia, and SCLC, and compares this association with patients with CV2-Ab and Hu-Ab.
19. Rosenfeld MR, Eichen JG, Wade DF, et al.: Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001, 50:339-348.
20. Shams'ili S, Grefkens J, de Leeuw B, et al.: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003, 126:1409-1418. This study reports the clinical and immunologic features of 50 patients with paraneoplastic cerebellar ataxia.
21. Alamowitch S, Graus F, Uchuya M, et al.: Limbic encephalitis and small cell lung cancer: clinical and immunological features. Brain 1997, 120:923-928.
22. Gultekin SH, Rosenfeld MR, Voltz R, et al.: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000, 123:1481-1494.
23. Antoine JC, Absi L, Honnorat J, et al.: Anti-amphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumours. Arch Neurol 1999, 56:172-177.
24. Dalmau J, Graus F, Villarejo A, et al.: Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127:1831-1844. This article carefully describes clinical features of patients with Ma2-Ab.
25. Vincent A, Buckley C, Schott JM, et al.: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127:701-712. This article describes a new type of nonparaneoplastic limbic encephalitis associated with antivoltage gate potassium channel.
26. Pranzatelli MR, Tate ED, Wheeler A, et al.: Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002, 27:384-387.
27. Gambini C, Conte M, Bernini G, et al.: Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003, 442:555-562.
28. Luque FA, Furneaux HM, Ferziger R, et al.: Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991, 29:241-251.
29. Pittock SJ, Lucchinetti CF, Lennon VA: Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003, 53:580-587. This study reports the clinical and immunologic features of 34 patients with Ri-Ab.
30. Bataller L, Graus F, Saiz F, et al.: Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001, 124:437-443.
31. Bataller L, Rosenfeld MR, Graus F, et al.: Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003, 53:347-353. The authors report the serologic screening of a cDNA brainstem library with the sera of 21 patients with opsomyoclonus syndrome. A variety of neuronal antigens were cloned, suggesting different mechanisms in the pathophysiology of this syndrome.
32. Graus F, Keime-Guibert F, Ren̄é R, et al.: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
33. Bataller L, Dalmau J: Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 2004, 17:3-8. An extensive review of paraneoplastic syndromes that can be observed in neuroophthalmology.
34. Keltner JL, Thirkill CE: Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 1998, 126:296-302.
35. Shiraga S, Adamus G: Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002, 132:72-82.
36. Ohguro H, Nakazawa M: Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002, 514:109-124.
37. Keltner JL, Thirkill CE, Yip PT: Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001, 21:173-187.
38. Alexander KR, Barnes CS, Fishman GA, et al.: Contrast-processing deficits in melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 2004, 45:305-310.
39. Milam AH, Saari JC, Jacobson SG, et al.: Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993, 34:91-100.
40. De la Sayette V, Bertran F, Honnorat J, et al.: Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998, 55:405-408.
41. Cross SA, Salomao DR, Parisi JE, et al.: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-S-IgG. Ann Neurol 2003, 54:38-50. The authors report 16 patients with optic neuritis, retinitis, or both, selected from a large series of patients with CV2-Ab and PNS. Most patients had SCLC.
42. Folli F, Solimena M, Cofiell R, et al.: Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993, 328:546-551.
43. Petzold GC, Marcucci M, Butler MH, et al.: Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. Ann Neurol 2004, 55:286-290. The authors report the occurrence of rhabdomyolysis in a patient with SPS, breast cancer, and amphiphysin-Ab. Immunotherapy induced a remission of both rhabdomyolysis and SPS.
44. De Giorgio R, Guerrini S, Barbara G, et al.: Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004, 126:1872-1883. An extensive review of inflammatory neuropathy of the enteric nervous system. The clinical picture that reflects the involved segment of the gastrointestinal tract (achalasia, gastroparesis, pseudo-obstruction, and megacolon) and the immunologic specificities are described.
45. Molinuevo JL, Graus F, Serrano C, et al.: Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998, 44:976-980.
46. Dalmau J, Graus F, Rosenblum MK, et al.: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992, 71:59-72.
47. Camdessanché JP, Antoine JC, Honnorat J, et al.: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 2002, 125:166-175.
48. Wabbels BK, Elflein H, Lorenz B, et al.: Bilateral tonic pupils with evidence of anti-hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica 2004, 218:141-143.
49. Georgian-Smith D, Ellis GK, Kraft GH: Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma. Breast J 2003, 9:316-318.
50. Scheid R, Honnorat J, Delmont E, et al.: A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry 2004, 75:338-340. The report of a novel antibody in a patient with breast cancer and limbic encephalitis.
51. Cartalat-Carel S, Camdessanche JP, Ricard D, et al.: The paraneoplastic neurological syndrome associated with anti-CV2 (anti-CRMP5) antibodies is different from that of anti-Hu antibodies. Neurology 2004, 62(suppl 5):A476-A477. This study presents preliminary data showing the clinical differences in patients with CV2-Ab and Hu-Ab.
52. Chartran-Lefebvre C, Howarth HN, Grenier P, et al.: Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiological and CT findings. AJR Am J Roentgenol 1998, 170:1513-1517.
53. 18FDG-PET improves tumor detection in patients with paraneoplastic neurological syndromes. Brain 2004, Epub ahead of print. The authors studied 20 consecutive patients with suspected PNS to determine the specificity and sensitivity of whole body FDG-PET to identify the tumor early.
54. 18F] fluorodeoxyglucose positon emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000, 48:105-108.
55. 18F]fluoro- 2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001, 124:2223-2231.
56. Luchinetti CF, Kimmel DW, Lennon V: Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear antibodies. Neurology 1998, 50:652-657.
57. Keime-Guibert F, Graus F, Fleury A, et al.: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479-482.
58. Vernino S, O'Neill BP, Marks RS, et al.: Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004, 6:55-62. The authors report in patients with PNS a prospective open-label treatment study of plasma exchange plus conventional cancer chemotherapy (10 patients) or plasma exchange plus continuous oral cyclophosphamide (10 patients). They conclude that an aggressive immunosuppression early in the clinical course should be considered in patients who have PNS even when there is no evidence of active malignancy.
59. Widdess-Walsh P, Tavee JO, Schuele S, et al.: Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003, 63:187-190. An extensive review of the literature of patients with paraneoplastic cerebellar ataxia treated by intravenous immunoglobulin.
60. Kim YI: Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986, 9:523-530.
61. Sakai K, Kitagawa Y, Saiki S, et al.: Effect of a paraneoplastic cerebellar degeneration-associated neural protein on B-myb promoter activity. Neurobiol Dis 2004, 15:529-533. The authors report experimental data showing that Yo-Ab delivered into the cells inhibits the repression of B-myb. Because derepression of the B-myb promoter has been implicated in neuronal death, the results suggest the possible role of Yo-Ab in the pathogenesis of PNS.
62. Ricard D, Rogemond V, Charrier E, et al.: Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a-sensitive oligodendrocytes. J Neurosci 2001, 21:7203-7214.
63. Okano HJ, Park WY, Corradi JP, et al.: The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 1999, 13:2087-2097.
64. Tanaka K, Ding X, Tanaka M: Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurosci 2004, 217:25-30. In this study, the authors examined the effects of Yo-Ab and Hu-Ab on mouse brain-derived neurons in a primary culture system and found that these antibodies did not kill neurons but induced the expression of cell adhesion molecules and accelerated neuronal differentiation. However, these effects did not occur through the binding of the antibody to specific antigens, but through some other factors contained in IgG fractions.
65. Graus F, Illa I, Agusti M, et al.: Effect of intraventricular injection of anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991, 106:82-87.
66. Albert ML, Austin L, Darnell RB: Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
67. Plonquet A, Garcia-Pons F, Fernandez E, et al.: Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 2003, 142:93-100. The authors examined MHC class I-restricted immunogenicity of human Hu antigen. Among 14 HuD-derived peptides potentially immunogenic in HLA-A*0201 restriction, only one was naturally processed and presented to the immune system.
68. Sutton IJ, Steele J, Savage CO, et al.: An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 2004, 150:98-106. The authors provide experimental evidences suggesting a very limited role for CTL-mediated tumor immunity in patients with PNS and Yo-Ab.
69. Carpentier AF, Rosenfeld MR, Delattre, et al.: DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998, 4:2819-2824.
70. Graus F, Dalmou J, Rene R, et al.: Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997, 15:2866-2672.
71. Antoine JC, Honnorat J, Camdessanche JP, et al.: Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001, 49:214-221.
72. DuHadaway JB, Sakamuro D, Ewert DL, et al.: Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res 2001, 61:3151-3156.
73. Levine TD, Gao F, King PH, et al.: Hel-N1: an autoimmune RNA-binding protein with specificity for 3′ uridylate-rich untranslated regions of growth factor mRNAs. Mol Cell Biol 1993, 13:3494-3504.
74. Chang CC, Shih JY, Jeng YM, et al.: Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004, 96:364-375. By an experimental method using cell transfection, the authors demonstrate that CTGF inhibits metastasis and invasion of human lung adenocarcinoma by a CRMP-1-dependent mechanism (CRMP proteins are CV2-Ab antigens).